Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Healthcare Drug Manufacturers - Specialty & Generic
Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Nuvo Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(1)
•••
Post by VictorKonstanon Jun 14, 2017 4:51pm
310 Views
Post# 26363509

June Investor Presentation

June Investor Presentation Typical....and not surprising!  No sense of urgency while the patent clock ticks on and on to lost revenue and ultimately, P2 oblivion...
Excellent effective product but unfortunately without competent management, it goes nowhere.
Also....What's happening with P2 sales and launch in Russia with NovaMedica....?
And...no news or updates regarding the total failure of the European P2 trials?
Perhaps Hendrick deserves a raise....all this management team seems to do is congratulate and enrich each other for doing absolutely nothing!
Incompetent people love to sweep their mistakes and failures under the carpet...
Just wait until they start blaming others for their own inadequacies and incompetence!

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities